Nuwellis, Inc. Reports Third Quarter 2022 Financial Results
08 nov. 2022 08h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial...
Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates
03 nov. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NasdaqCM: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the...
Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022
19 oct. 2022 16h15 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022. The company...
Nuwellis Announces Appointment of Chief Financial Officer
19 oct. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Continuing its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload,...
Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
18 oct. 2022 16h15 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage company focused on transforming the lives of people with fluid...
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering
14 oct. 2022 08h30 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid...
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
03 oct. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results...
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial
27 sept. 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the...
Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
31 août 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the...
U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology
25 août 2022 07h00 HE
|
Nuwellis, Inc.
MINNEAPOLIS, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) a commercial stage company dedicated to transforming the lives of patients suffering from fluid overload, today announced...